Sinopam vaccine reaches 1 million in China, clinical trials in Peru cease … Participant’s leg paralysis

Entry 2020.12.14 08:22

The Peruvian government has stopped clinical trials of the Chinese sinofam vaccine. One of the participants suffered from neurological problems that showed difficulty moving his legs.

According to the Wall Street Journal (WSJ) on the 13th (local time), the Peruvian health authorities the day before said: “Clinical trials of the Sinopam vaccine in China will be suspended due to health problems that appeared to the participants.”

Sinoparm was conducting a clinical trial in Peru with 12,000 participants and the trial was expected to be completed in a few days.

However, as one participant struggled to use his leg, Peruvian health authorities decided to stop the test.

A Peruvian health official said the participant had symptoms similar to Guillain-Barré syndrome.

Guillain-Barré syndrome is an unknown cause of inflammation in the peripheral nerves, mainly causing pain and paralysis in the extremities. It occurs as often as 10 to 20 per year per million adults, and there are cases of side effects from the influenza (flu) vaccine.

What type of sinopam vaccine was used in this trial was not disclosed.

China has said that 1 million people in its country have been vaccinated with the sinofam vaccine, but no side effects have been reported.

However, it is causing concern among medical officials around the world, as detailed data, including cases of infection, which are the basis for estimating efficacy, have not been disclosed.

The Synofam vaccine is currently in clinical trials in Argentina, Bahrain, Egypt, Indonesia, Jordan, Morocco, and Russia, and vaccination has started in Egypt and Indonesia. On the 8th, the UAE government officially approved the use.